Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 721

Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany

Dr Sonja Loges talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of the AXL inhibitor bemcentinib in combination with LDAC or decitabine in AML patients unfit for intensive chemotherapy.

She explains that a promising overall response rate of 46% was seen with most of the responses coming after one or two cycles of treatment.

Dr Loges acknowledges that the sample size of the study is still small but that an expansion of the cohorts is planned to increase the number of patients.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation